Visceral Adiposity and Progression of ADPKD: A Cohort Study of Patients From the TEMPO 3:4 Trial.

ABSTRACT:

Rationale & objective

Body mass index (BMI) is an independent predictor of kidney disease progression in individuals with autosomal dominant polycystic kidney disease (ADPKD). Adipocytes do not simply act as a fat reservoir but are active endocrine organs. We hypothesized that greater visceral abdominal adiposity would associate with more rapid kidney growth in ADPKD and influence the efficacy of tolvaptan.

Study design

A retrospective cohort study.

Setting & participants

1,053 patients enrolled in the TEMPO 3:4 tolvaptan trial with ADPKD and at high risk of rapid disease progression.

Predictor

Estimates of visceral adiposity extracted from coronal plane magnetic resonance imaging (MRI) scans using deep learning.

Outcome

Annual change in total kidney vol

SUBMITTER: Nowak KL 

PROVIDER: S-EPMC11344693 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature